Rimiducid: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006...